PRS 080

Drug Profile

PRS 080

Alternative Names: PRS 080#022-DP; PRS080

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Antianaemics; Lipocalins
  • Mechanism of Action Hepcidin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Iron deficiency anaemia

Most Recent Events

  • 30 Sep 2017 Phase-II clinical trials in Iron deficiency anaemia in Czech Republic, Germany (IV) (NCT03325621)
  • 09 Aug 2017 Pieris Pharmaceuticals announces intention to submit clinical trial applications in Germany and the Czech Republic for Anaemia in the third quarter of 2017
  • 05 Jul 2017 Pieris Pharmaceuticals plans a multi-dose trial for Iron deficiency anaemia in Germany and Czech Republic in the third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top